Big Pharma is gambling on specialized R&D. Will it pay off?

BioPharma DiveAfter raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets

CellNociceptive innervation limits tertiary lymphoid structures to promote lung cancer

CellGenome instability triggers intercellular DNA transfer between human cells

FierceBiotechWith $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate

FierceBiotechLilly pens $202M deal for preclinical DNA delivery biotech Engage as M&A streak continues

BioPharma DiveBristol Myers deepens AI investment with Anthropic deal

BioPharma DiveOorja, run by Acceleron veterans, launches to make new fibrosis drugs

Endpoints NewsPfizer's next-gen pneumonia shot beats Prevnar 20; Relay targets $175M

Clinical OMICsAnti-Inflammatory Drug Could Help Some People with Depression

BioPharma DiveImmunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

FierceBiotechBMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows

FierceBiotechIncyte pays Genesis $80M to expand AI-fueled drug discovery pact